Current and Past Colorado NORC Pilot Awardees

Funding Year 2024

Funding Year 2023

steele

Cortney Steele PhD

Post-Doctoral Fellow
  • Renal Medicine (SOM)
  • School of Medicine

Dates of Funding: 2022-2024
I am currently a Post-Doctoral Fellow at the University of Colorado, Anschutz Medical Campus in the Division of Renal Disease and Hypertension. My long-term career goal is to become an independent research scientist with a focus on the interaction of lifestyle behaviors and health outcomes in individuals with kidney disease. I am supported by an NIDDK F32 fellowship, which focuses on patients with autosomal dominant polycystic kidney disease (ADPKD).  ADPKD is the most commonly inherited progressive kidney disease. Overweight and obese phenotypes have been associated with disease progression in early-stage ADPKD. Daily caloric restriction (DCR, 34% restriction per day from baseline weight maintenance requirements) may aid in weight loss and ultimately slow ADPKD disease progression. Weight loss via DCR may cause alterations in kidney oxidative metabolism and insulin sensitivity that can affect ADPKD disease progression. For my NORC pilot award, I will assess kidney oxidative metabolism and insulin sensitivity by leveraging an ongoing R01-funded trial (NCT04907799) in DCR vs. control groups at baseline (BSL) and 2 years. I will also utilize the clinical outcome measures performed in the parent trial to address the subsequent novel aims: Aim 1: Compare kidney oxidative metabolism and insulin sensitivity at BSL and 2 years in adults with ADPKD. Aim 2: Define the relations among changes in kidney oxidative metabolism, insulin sensitivity, total kidney volume, and weight over 2 years. Currently, it is unknown if weight loss via DCR modifies renal energy expenditure and substrate utilization. Collectively, this award will provide an opportunity to collect novel preliminary data and training for a future career development grant.

Funding Year 2022

steele

Cortney Steele PhD

Post-Doctoral Fellow
  • Renal Medicine (SOM)
  • School of Medicine

Dates of Funding: 2022-2024
I am currently a Post-Doctoral Fellow at the University of Colorado, Anschutz Medical Campus in the Division of Renal Disease and Hypertension. My long-term career goal is to become an independent research scientist with a focus on the interaction of lifestyle behaviors and health outcomes in individuals with kidney disease. I am supported by an NIDDK F32 fellowship, which focuses on patients with autosomal dominant polycystic kidney disease (ADPKD).  ADPKD is the most commonly inherited progressive kidney disease. Overweight and obese phenotypes have been associated with disease progression in early-stage ADPKD. Daily caloric restriction (DCR, 34% restriction per day from baseline weight maintenance requirements) may aid in weight loss and ultimately slow ADPKD disease progression. Weight loss via DCR may cause alterations in kidney oxidative metabolism and insulin sensitivity that can affect ADPKD disease progression. For my NORC pilot award, I will assess kidney oxidative metabolism and insulin sensitivity by leveraging an ongoing R01-funded trial (NCT04907799) in DCR vs. control groups at baseline (BSL) and 2 years. I will also utilize the clinical outcome measures performed in the parent trial to address the subsequent novel aims: Aim 1: Compare kidney oxidative metabolism and insulin sensitivity at BSL and 2 years in adults with ADPKD. Aim 2: Define the relations among changes in kidney oxidative metabolism, insulin sensitivity, total kidney volume, and weight over 2 years. Currently, it is unknown if weight loss via DCR modifies renal energy expenditure and substrate utilization. Collectively, this award will provide an opportunity to collect novel preliminary data and training for a future career development grant.

Funding Year 2021

steele

Cortney Steele PhD

Post-Doctoral Fellow
  • Renal Medicine (SOM)
  • School of Medicine

Dates of Funding: 2022-2024
I am currently a Post-Doctoral Fellow at the University of Colorado, Anschutz Medical Campus in the Division of Renal Disease and Hypertension. My long-term career goal is to become an independent research scientist with a focus on the interaction of lifestyle behaviors and health outcomes in individuals with kidney disease. I am supported by an NIDDK F32 fellowship, which focuses on patients with autosomal dominant polycystic kidney disease (ADPKD).  ADPKD is the most commonly inherited progressive kidney disease. Overweight and obese phenotypes have been associated with disease progression in early-stage ADPKD. Daily caloric restriction (DCR, 34% restriction per day from baseline weight maintenance requirements) may aid in weight loss and ultimately slow ADPKD disease progression. Weight loss via DCR may cause alterations in kidney oxidative metabolism and insulin sensitivity that can affect ADPKD disease progression. For my NORC pilot award, I will assess kidney oxidative metabolism and insulin sensitivity by leveraging an ongoing R01-funded trial (NCT04907799) in DCR vs. control groups at baseline (BSL) and 2 years. I will also utilize the clinical outcome measures performed in the parent trial to address the subsequent novel aims: Aim 1: Compare kidney oxidative metabolism and insulin sensitivity at BSL and 2 years in adults with ADPKD. Aim 2: Define the relations among changes in kidney oxidative metabolism, insulin sensitivity, total kidney volume, and weight over 2 years. Currently, it is unknown if weight loss via DCR modifies renal energy expenditure and substrate utilization. Collectively, this award will provide an opportunity to collect novel preliminary data and training for a future career development grant.

Funding Year 2020

steele

Cortney Steele PhD

Post-Doctoral Fellow
  • Renal Medicine (SOM)
  • School of Medicine

Dates of Funding: 2022-2024
I am currently a Post-Doctoral Fellow at the University of Colorado, Anschutz Medical Campus in the Division of Renal Disease and Hypertension. My long-term career goal is to become an independent research scientist with a focus on the interaction of lifestyle behaviors and health outcomes in individuals with kidney disease. I am supported by an NIDDK F32 fellowship, which focuses on patients with autosomal dominant polycystic kidney disease (ADPKD).  ADPKD is the most commonly inherited progressive kidney disease. Overweight and obese phenotypes have been associated with disease progression in early-stage ADPKD. Daily caloric restriction (DCR, 34% restriction per day from baseline weight maintenance requirements) may aid in weight loss and ultimately slow ADPKD disease progression. Weight loss via DCR may cause alterations in kidney oxidative metabolism and insulin sensitivity that can affect ADPKD disease progression. For my NORC pilot award, I will assess kidney oxidative metabolism and insulin sensitivity by leveraging an ongoing R01-funded trial (NCT04907799) in DCR vs. control groups at baseline (BSL) and 2 years. I will also utilize the clinical outcome measures performed in the parent trial to address the subsequent novel aims: Aim 1: Compare kidney oxidative metabolism and insulin sensitivity at BSL and 2 years in adults with ADPKD. Aim 2: Define the relations among changes in kidney oxidative metabolism, insulin sensitivity, total kidney volume, and weight over 2 years. Currently, it is unknown if weight loss via DCR modifies renal energy expenditure and substrate utilization. Collectively, this award will provide an opportunity to collect novel preliminary data and training for a future career development grant.

Funding Year 2019

steele

Cortney Steele PhD

Post-Doctoral Fellow
  • Renal Medicine (SOM)
  • School of Medicine

Dates of Funding: 2022-2024
I am currently a Post-Doctoral Fellow at the University of Colorado, Anschutz Medical Campus in the Division of Renal Disease and Hypertension. My long-term career goal is to become an independent research scientist with a focus on the interaction of lifestyle behaviors and health outcomes in individuals with kidney disease. I am supported by an NIDDK F32 fellowship, which focuses on patients with autosomal dominant polycystic kidney disease (ADPKD).  ADPKD is the most commonly inherited progressive kidney disease. Overweight and obese phenotypes have been associated with disease progression in early-stage ADPKD. Daily caloric restriction (DCR, 34% restriction per day from baseline weight maintenance requirements) may aid in weight loss and ultimately slow ADPKD disease progression. Weight loss via DCR may cause alterations in kidney oxidative metabolism and insulin sensitivity that can affect ADPKD disease progression. For my NORC pilot award, I will assess kidney oxidative metabolism and insulin sensitivity by leveraging an ongoing R01-funded trial (NCT04907799) in DCR vs. control groups at baseline (BSL) and 2 years. I will also utilize the clinical outcome measures performed in the parent trial to address the subsequent novel aims: Aim 1: Compare kidney oxidative metabolism and insulin sensitivity at BSL and 2 years in adults with ADPKD. Aim 2: Define the relations among changes in kidney oxidative metabolism, insulin sensitivity, total kidney volume, and weight over 2 years. Currently, it is unknown if weight loss via DCR modifies renal energy expenditure and substrate utilization. Collectively, this award will provide an opportunity to collect novel preliminary data and training for a future career development grant.

Funding Year 2018

steele

Cortney Steele PhD

Post-Doctoral Fellow
  • Renal Medicine (SOM)
  • School of Medicine

Dates of Funding: 2022-2024
I am currently a Post-Doctoral Fellow at the University of Colorado, Anschutz Medical Campus in the Division of Renal Disease and Hypertension. My long-term career goal is to become an independent research scientist with a focus on the interaction of lifestyle behaviors and health outcomes in individuals with kidney disease. I am supported by an NIDDK F32 fellowship, which focuses on patients with autosomal dominant polycystic kidney disease (ADPKD).  ADPKD is the most commonly inherited progressive kidney disease. Overweight and obese phenotypes have been associated with disease progression in early-stage ADPKD. Daily caloric restriction (DCR, 34% restriction per day from baseline weight maintenance requirements) may aid in weight loss and ultimately slow ADPKD disease progression. Weight loss via DCR may cause alterations in kidney oxidative metabolism and insulin sensitivity that can affect ADPKD disease progression. For my NORC pilot award, I will assess kidney oxidative metabolism and insulin sensitivity by leveraging an ongoing R01-funded trial (NCT04907799) in DCR vs. control groups at baseline (BSL) and 2 years. I will also utilize the clinical outcome measures performed in the parent trial to address the subsequent novel aims: Aim 1: Compare kidney oxidative metabolism and insulin sensitivity at BSL and 2 years in adults with ADPKD. Aim 2: Define the relations among changes in kidney oxidative metabolism, insulin sensitivity, total kidney volume, and weight over 2 years. Currently, it is unknown if weight loss via DCR modifies renal energy expenditure and substrate utilization. Collectively, this award will provide an opportunity to collect novel preliminary data and training for a future career development grant.

Funding Year 2017

steele

Cortney Steele PhD

Post-Doctoral Fellow
  • Renal Medicine (SOM)
  • School of Medicine

Dates of Funding: 2022-2024
I am currently a Post-Doctoral Fellow at the University of Colorado, Anschutz Medical Campus in the Division of Renal Disease and Hypertension. My long-term career goal is to become an independent research scientist with a focus on the interaction of lifestyle behaviors and health outcomes in individuals with kidney disease. I am supported by an NIDDK F32 fellowship, which focuses on patients with autosomal dominant polycystic kidney disease (ADPKD).  ADPKD is the most commonly inherited progressive kidney disease. Overweight and obese phenotypes have been associated with disease progression in early-stage ADPKD. Daily caloric restriction (DCR, 34% restriction per day from baseline weight maintenance requirements) may aid in weight loss and ultimately slow ADPKD disease progression. Weight loss via DCR may cause alterations in kidney oxidative metabolism and insulin sensitivity that can affect ADPKD disease progression. For my NORC pilot award, I will assess kidney oxidative metabolism and insulin sensitivity by leveraging an ongoing R01-funded trial (NCT04907799) in DCR vs. control groups at baseline (BSL) and 2 years. I will also utilize the clinical outcome measures performed in the parent trial to address the subsequent novel aims: Aim 1: Compare kidney oxidative metabolism and insulin sensitivity at BSL and 2 years in adults with ADPKD. Aim 2: Define the relations among changes in kidney oxidative metabolism, insulin sensitivity, total kidney volume, and weight over 2 years. Currently, it is unknown if weight loss via DCR modifies renal energy expenditure and substrate utilization. Collectively, this award will provide an opportunity to collect novel preliminary data and training for a future career development grant.

Funding Year 2016

Funding Year 2015

steele

Cortney Steele PhD

Post-Doctoral Fellow
  • Renal Medicine (SOM)
  • School of Medicine

Dates of Funding: 2022-2024
I am currently a Post-Doctoral Fellow at the University of Colorado, Anschutz Medical Campus in the Division of Renal Disease and Hypertension. My long-term career goal is to become an independent research scientist with a focus on the interaction of lifestyle behaviors and health outcomes in individuals with kidney disease. I am supported by an NIDDK F32 fellowship, which focuses on patients with autosomal dominant polycystic kidney disease (ADPKD).  ADPKD is the most commonly inherited progressive kidney disease. Overweight and obese phenotypes have been associated with disease progression in early-stage ADPKD. Daily caloric restriction (DCR, 34% restriction per day from baseline weight maintenance requirements) may aid in weight loss and ultimately slow ADPKD disease progression. Weight loss via DCR may cause alterations in kidney oxidative metabolism and insulin sensitivity that can affect ADPKD disease progression. For my NORC pilot award, I will assess kidney oxidative metabolism and insulin sensitivity by leveraging an ongoing R01-funded trial (NCT04907799) in DCR vs. control groups at baseline (BSL) and 2 years. I will also utilize the clinical outcome measures performed in the parent trial to address the subsequent novel aims: Aim 1: Compare kidney oxidative metabolism and insulin sensitivity at BSL and 2 years in adults with ADPKD. Aim 2: Define the relations among changes in kidney oxidative metabolism, insulin sensitivity, total kidney volume, and weight over 2 years. Currently, it is unknown if weight loss via DCR modifies renal energy expenditure and substrate utilization. Collectively, this award will provide an opportunity to collect novel preliminary data and training for a future career development grant.

Funding Year 2014

steele

Cortney Steele PhD

Post-Doctoral Fellow
  • Renal Medicine (SOM)
  • School of Medicine

Dates of Funding: 2022-2024
I am currently a Post-Doctoral Fellow at the University of Colorado, Anschutz Medical Campus in the Division of Renal Disease and Hypertension. My long-term career goal is to become an independent research scientist with a focus on the interaction of lifestyle behaviors and health outcomes in individuals with kidney disease. I am supported by an NIDDK F32 fellowship, which focuses on patients with autosomal dominant polycystic kidney disease (ADPKD).  ADPKD is the most commonly inherited progressive kidney disease. Overweight and obese phenotypes have been associated with disease progression in early-stage ADPKD. Daily caloric restriction (DCR, 34% restriction per day from baseline weight maintenance requirements) may aid in weight loss and ultimately slow ADPKD disease progression. Weight loss via DCR may cause alterations in kidney oxidative metabolism and insulin sensitivity that can affect ADPKD disease progression. For my NORC pilot award, I will assess kidney oxidative metabolism and insulin sensitivity by leveraging an ongoing R01-funded trial (NCT04907799) in DCR vs. control groups at baseline (BSL) and 2 years. I will also utilize the clinical outcome measures performed in the parent trial to address the subsequent novel aims: Aim 1: Compare kidney oxidative metabolism and insulin sensitivity at BSL and 2 years in adults with ADPKD. Aim 2: Define the relations among changes in kidney oxidative metabolism, insulin sensitivity, total kidney volume, and weight over 2 years. Currently, it is unknown if weight loss via DCR modifies renal energy expenditure and substrate utilization. Collectively, this award will provide an opportunity to collect novel preliminary data and training for a future career development grant.

Colorado Nutrition Obesity Research Center (NORC)

CU Anschutz Health and Wellness Center

12348 East Montview Boulevard

Aurora, CO 80045


norc@cuanschutz.edu

CMS Login